Studies have shown that they are over-regulated in atherosclerosis and negatively related to plasma cholesterol and ATP-binding cassette transporter A1 (ABCA1) levels, representing a new biomarker for clinical diagnosis and treatment of coronary atherosclerosis [32]. This evidence concerns the gene ABCA1 and coronary atherosclerosis.